Zur Rose Group AG

  • ISIN: CH0042615283
  • Land: Schweiz

Nachricht vom 15.06.2021 | 07:00

Zur Rose Group strengthens Group Management: Madhu Nutakki to become Chief Technology Officer

EQS Group-News: Zur Rose Group AG / Key word(s): Personnel
15.06.2021 / 07:00

 
Frauenfeld, 15 June 2021
Press release
 

Zur Rose Group strengthens Group Management: Madhu Nutakki to become Chief Technology Officer

Madhu Nutakki will take on the newly created position of Chief Technology Officer (CTO) of the Zur Rose Group on 1 August 2021. As a member of the Group Management, Madhu Nutakki will be responsible for establishing a flexible Group technology platform, which will develop into Zur Rose's European healthcare ecosystem, and for the functional management of the CTOs of the geographical segments and their tech hubs. As part of this Group-wide responsibility, he will help shape and mould the company's technical innovation and transformation into a healthtech provider.

With his well-founded industry-relevant expertise and many years of technology experience, the 49-year-old US national brings with him the ideal prerequisites to play this very significant role for the company. Madhu Nutakki spent twelve years at Kaiser Permanente, the largest organisation for integrated non-profit healthcare in the USA, in various management positions, most recently as V.P. Digital Health Applications and Platforms. Previously, he worked at American International Group (AIG) insurance company in New York, USA, for three years as Chief Technology Officer and Global Digital Head. He is currently with Nissan Motor Corporation in Japan as Global Head of Customer Experience and Connected Car. Madhu Nutakki holds a master's degree in Computer Engineering from Iowa State University and completed an Executive Business Management program at the Wharton School of Management at the University of Pennsylvania.

"As part of our positioning as a comprehensive healthcare provider and leading technology company, our technological foundation and digital innovation are of strategic importance," says Walter Oberhänsli, CEO of the Zur Rose Group. "We are therefore very pleased to have recruited Madhu Nutakki for the CTO position. As a highly qualified leader in an international environment, he is a valuable and optimal addition to the existing management team."
 

Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Group Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Agenda

16 June 2021 Capital Markets Day
18 August 2021 Half-Year Results
21 October 2021 Q3 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand, DocMorris, and employs more than 2,200 people at sites in Switzerland, Germany, the Netherlands, Spain and France. Now serving more than 11 million active customers in core European markets, Zur Rose generated revenue of CHF 1,752 million (including external revenue) in 2020.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It also excels in continuous development of digital healthcare services and as a platform technology provider. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Zur Rose's contribution will be to bring these offerings to customers and patients, pursuing its vision of creating a world where people can manage their own health in one click.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit zurrosegroup.com.



End of Media Release



show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

News im Fokus

Vonovia SE: Vonovia verkauft Berliner Wohnungsbestände aus dem Zukunfts- und Sozialpakt Wohnen

17. September 2021, 12:40

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

CR Capital AG

Original-Research: CR Capital AG (von First Berlin Equity Research GmbH): Buy

17. September 2021